Evaluation of Aspirin Use for Primary Prevention in Diabetic Patients

Abstract

Get full access to this article

View all access options for this article.

References

Fosmire Rundgren

Anderson

Marrs

. Evaluation of aspirin use in patients with diabetes receiving care in community health [published online October 6, 2014]. Ann Pharmacother. doi:10.1177/1060028014554444.

Ogawa

Nakayama

Morimoto

; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134-2141.

Belch

MacCuish

Campbell

; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.

Antithrombotic Trialists’ (ATT) Collaboration; Baigent

Blackwell

Collins

. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.

Stone

Robinson

Lichtenstein

; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25, suppl 2):S1-S45.